Novo Nordisk ADR (NYSE: NVO) currently trades at $89 per share, nearly 40% below its peak level of over $145 seen in June of ...

Trials of semaglutide in patients with Alzheimer’s and CagriSema in obese patients diabetes could give investors reason to be ...

Europe's STOXX 600 closed slightly higher at the start of a holiday-shortened week, as a spike in Novo Nordisk shares boosted ...

Lilly and Novo still dominate the market for weight-loss and diabetes drugs, but the race is heating up in more ways than one ...

Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug ...

CagriSema, a drug that Novo had hoped would become the next generation weight-loss aid, failed to meet expectations in ...

As of 11:05 a.m. ET, Novo Nordisk stock is down a disheartening 20.8%, while both Lilly and Viking stocks are up 4.4% apiece.

Novo Nordisk shareholders were seeking on Friday to find out why such a high number of patients in the late-stage trial of ...

Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently ...

The Ozempic maker's stock tanked after its highly anticipated CagriSema drug trial showed an average of 22.7% weight loss, ...

Shares in Ozempic maker Novo Nordisk crashed, after an experimental anti-obesity shot fell short of expectations. The shares ...

Novo Nordisk ’s big bet to improve on the success of its weight-loss drug franchise hit a stumbling block Friday, wiping out ...